Kailera Therapeutics, Inc. Common Stock KLRA
$16.23
+3.11%
at last close
Market Cap$2.10 billion
P/E Ratio—
Div Yield—
Volume524.4K
52-Week Range
$15.15$28.23
Analyst Ratings
- Consensus
- Buy — 4 Buy · 0 Hold · 0 Sell (4 analysts)
- Avg. Price Target
- $38.00 (+134.1% upside)
Key Stats
- Today's Range
- $15.57 – $16.44
- 50-Day Range
- $15.15 – $23.82
- 52-Week Range
- $15.15 – $28.23
- Volume
- 524K shs
- Average Volume
- 619K shs
- Market Cap
- $2.10 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 1.51%
- Days to Cover
- 1.15
About Kailera Therapeutics, Inc. Common Stock
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
Related Stocks
Compare head-to-head: KLRA vs LLY·KLRA vs JNJ·KLRA vs ABBV·KLRA vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.